Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review

John Koreth, Edwin P. Alyea, William J Murphy, Lisbeth A. Welniak

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of allogeneic hematopoietic stem cell transplantation (HSCT), both for the control of transplant-related toxicities like acute and chronic graft-versus-host disease (aGVHD, cGHVHD), and for improved malignant disease control after allogeneic HSCT.

Original languageEnglish (US)
Pages (from-to)1502-1512
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Proteasome Endopeptidase Complex
Graft vs Host Disease
Ubiquitin
Multiple Myeloma
Transplants
Therapeutics
Neoplasms
Proteins

Keywords

  • Acute GVHD
  • Bortezomib
  • Chronic GVHD
  • Graft-versus tumor
  • NFkb

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation : A Review. / Koreth, John; Alyea, Edwin P.; Murphy, William J; Welniak, Lisbeth A.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 12, 12.2009, p. 1502-1512.

Research output: Contribution to journalArticle

Koreth, John ; Alyea, Edwin P. ; Murphy, William J ; Welniak, Lisbeth A. / Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation : A Review. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 12. pp. 1502-1512.
@article{59c2e42fdfb84c6cb520f0a257c509dc,
title = "Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review",
abstract = "The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of allogeneic hematopoietic stem cell transplantation (HSCT), both for the control of transplant-related toxicities like acute and chronic graft-versus-host disease (aGVHD, cGHVHD), and for improved malignant disease control after allogeneic HSCT.",
keywords = "Acute GVHD, Bortezomib, Chronic GVHD, Graft-versus tumor, NFkb",
author = "John Koreth and Alyea, {Edwin P.} and Murphy, {William J} and Welniak, {Lisbeth A.}",
year = "2009",
month = "12",
doi = "10.1016/j.bbmt.2009.07.016",
language = "English (US)",
volume = "15",
pages = "1502--1512",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation

T2 - A Review

AU - Koreth, John

AU - Alyea, Edwin P.

AU - Murphy, William J

AU - Welniak, Lisbeth A.

PY - 2009/12

Y1 - 2009/12

N2 - The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of allogeneic hematopoietic stem cell transplantation (HSCT), both for the control of transplant-related toxicities like acute and chronic graft-versus-host disease (aGVHD, cGHVHD), and for improved malignant disease control after allogeneic HSCT.

AB - The proteasome and its associated ubiquitin protein modification system have proved to be an important therapeutic target in the treatment of multiple myeloma and other cancers. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on nonneoplastic immune cells. This indicates that proteasome inhibition, through the use of agents like bortezomib, could be used therapeutically to modulate immune responses. In this review we explore the emerging data, both preclinical and clinical, highlighting the importance of proteasome targeting of immunologic responses, primarily in the context of allogeneic hematopoietic stem cell transplantation (HSCT), both for the control of transplant-related toxicities like acute and chronic graft-versus-host disease (aGVHD, cGHVHD), and for improved malignant disease control after allogeneic HSCT.

KW - Acute GVHD

KW - Bortezomib

KW - Chronic GVHD

KW - Graft-versus tumor

KW - NFkb

UR - http://www.scopus.com/inward/record.url?scp=70350786880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350786880&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.07.016

DO - 10.1016/j.bbmt.2009.07.016

M3 - Article

C2 - 19896073

AN - SCOPUS:70350786880

VL - 15

SP - 1502

EP - 1512

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -